LMND:NYSELemonade, Inc. Analysis
Data as of 2026-06-13 - not real-time
$57.49
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Lemonade’s share price of $57.49 sits just above its 20‑day SMA (55.52) but remains below the 50‑day (58.25) and 200‑day (63.93) averages, indicating short‑term momentum yet a longer‑term bearish bias. The MACD line has crossed above its signal line, generating a bullish histogram (+0.38), while the RSI sits at a neutral 53.6, suggesting limited upside pressure as the stock approaches its resistance near $60.80. Volatility is extreme at 55% over the past 30 days and the beta of 2.52 signals amplified moves relative to the market, heightening short‑term risk.
Fundamentally, LMND posted a 71% revenue surge to $845 M and a solid 53% gross margin, but operating margins are still negative (‑11%) and earnings per share remain deeply in the red (‑$2.07 trailing, ‑$0.38 forward). The DCF fair value of $45.39 is well below the current price, implying the stock is priced above intrinsic estimates, while the P/B of 8.5 and negative forward P/E (‑153) reinforce an overvalued profile despite a modest analyst consensus target of $62.
Fundamentally, LMND posted a 71% revenue surge to $845 M and a solid 53% gross margin, but operating margins are still negative (‑11%) and earnings per share remain deeply in the red (‑$2.07 trailing, ‑$0.38 forward). The DCF fair value of $45.39 is well below the current price, implying the stock is priced above intrinsic estimates, while the P/B of 8.5 and negative forward P/E (‑153) reinforce an overvalued profile despite a modest analyst consensus target of $62.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance at $60.80
- High volatility and beta
- Negative earnings and operating loss
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 71% YoY revenue growth
- Management guidance toward positive adjusted EBITDA by Q4 2026
- Analyst median target of $62
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- AI‑driven insurance model and market expansion
- Persistent regulatory and profitability challenges
- Overvalued valuation multiples relative to intrinsic fair value
Key Metrics & Analysis
Financial Health
Revenue Growth70.60%
Profit Margin-16.44%
P/E Ratio-153.3
ROE-26.12%
ROA-3.51%
Debt/Equity38.69
P/B Ratio8.5
Op. Cash Flow$30.1M
Free Cash Flow$90.9M
Industry P/E16.8
Technical Analysis
TrendBearish
RSI53.6
Support$50.25
Resistance$60.80
MA 20$55.52
MA 50$58.25
MA 200$63.93
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$45.39
Target Price$62.00
Upside/Downside7.84%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.52
Volatility55.10%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.